Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study - Schultheis, Beate; Folprecht, Gunnar; Kuhlmann, J.; Ehrenberg, Karl Roland; Hacker, U. T.; Köhne, Claus-Henning; Kornacker, Martin; Cruzà Boix, Oreto; Lettieri, O.; Krauß, Jürgen; Fischer, R.; Hamann, Susanne; et al. (Annals of oncology, 2013)
Gesehen am 22.07.2021